Zepbound_12.5mg

Zepbound 12.5 mg is a prescription medication containing tirzepatide, a dual GLP-1 and GIP receptor agonist. Approved by the FDA for weight management, it is intended for adults with obesity or overweight conditions associated with weight-related medical problems. Administered as a once-weekly injection, Zepbound is typically used in conjunction with a reduced-calorie diet and increased physical activity to help individuals lose excess body weight and maintain weight loss.

The recommended dosing schedule for Zepbound begins with a starting dose of 2.5 mg once weekly for the first four weeks. Subsequent doses may be increased by 2.5 mg increments every four weeks, based on individual response and tolerability, up to a maximum of 15 mg per week. The 12.5 mg dose is typically administered during weeks 17–20 of the treatment regimen.